Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30072173HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072174HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072175HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072176HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072177HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072178HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072179HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072180HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072181HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072182HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TCGA Plot Options
Drug Information
GeneABL1
DrugBank IDDB12323
Drug NameRadotinib
Target IDBE0000014
UniProt IDP00519
Regulation Typeantagonist
PubMed IDs24705186
CitationsKim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW: Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.
GroupsInvestigational
Direct ClassificationBenzanilides
SMILESCC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=N3)=C2)=CC(=C1)C(F)(F)F
Pathways
PharmGKB
ChEMBL